Review article · 2021 · Open access

Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis

Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, Daniel J. Baillache, Stephen Croke, Asier Unciti‐Broceta

Journal of Medicinal Chemistry, 65(2), 1047–1131 · Published 8 October 2021 · DOI 10.1021/acs.jmedchem.1c00963

Open full textCite this paper

In brief

“Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis” is a 2021 review article by Cecilia C. Ayala-Aguilera and 5 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 305 citations as of 19 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Journal of Medicinal Chemistry.

Citations
305
Most cited in
2024 (72)
Field-weighted impact
4.82
References
563
Authors
6

Abstract

The central role of dysregulated kinase activity in the etiology of progressive disorders, including cancer, has fostered incremental efforts on drug discovery programs over the past 40 years. As a result, kinase inhibitors are today one of the most important classes of drugs. The FDA approved 73 small molecule kinase inhibitor drugs until September 2021, and additional inhibitors were approved by other regulatory agencies during that time. To complement the published literature on clinical kinase inhibitors, we have prepared a review that recaps this large data set into an accessible format for the medicinal chemistry community. Along with the therapeutic and pharmacological properties of each kinase inhibitor approved across the world until 2020, we provide the synthesis routes originally used during the discovery phase, many of which were only available in patent applications. In the last section, we also provide an update on kinase inhibitor drugs approved in 2021.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021). Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 65(2), 1047–1131. https://doi.org/10.1021/acs.jmedchem.1c00963

MLA 9

Ayala-Aguilera, Cecilia C., et al. “Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis.” Journal of Medicinal Chemistry, vol. 65, no. 2, 2021, pp. 1047–1131. https://doi.org/10.1021/acs.jmedchem.1c00963.

Chicago

Ayala-Aguilera, Cecilia C., Teresa Valero, Álvaro Lorente‐Macías, Daniel J. Baillache, Stephen Croke, and Asier Unciti‐Broceta. 2021. “Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis.” Journal of Medicinal Chemistry 65 (2): 1047–1131. https://doi.org/10.1021/acs.jmedchem.1c00963.

Harvard

Ayala-Aguilera, C. C. et al. (2021) ‘Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis’, Journal of Medicinal Chemistry, 65(2), pp. 1047–1131. doi:10.1021/acs.jmedchem.1c00963.

IEEE

C. C. Ayala-Aguilera, T. Valero, Á. Lorente‐Macías, D. J. Baillache, S. Croke, and A. Unciti‐Broceta, “Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis,” Journal of Medicinal Chemistry, vol. 65, no. 2, pp. 1047–1131, 2021, doi: 10.1021/acs.jmedchem.1c00963.

BibTeX

@article{ayalaaguilera2021small,
  title     = {{Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis}},
  author    = {Ayala-Aguilera, Cecilia C. and Valero, Teresa and Lorente‐Macías, Álvaro and Baillache, Daniel J. and Croke, Stephen and Unciti‐Broceta, Asier},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2021},
  volume    = {65},
  number    = {2},
  pages     = {1047--1131},
  doi       = {10.1021/acs.jmedchem.1c00963},
  url       = {https://doi.org/10.1021/acs.jmedchem.1c00963}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20224646
20236868
20247272
20256464
20265555

Its field-weighted citation impact is 4.82: it has been cited 4.82 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling

  • small-molecule kinase inhibitors
  • FDA-approved drugs
  • kinase inhibitor synthesis
  • drug discovery
  • pharmacology
  • treatment indications
  • cancer therapy
  • patents

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021). Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 65(2), 1047–1131. https://doi.org/10.1021/acs.jmedchem.1c00963

How many times has this paper been cited?

305 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Medicinal Chemistry: sign in and open the full text from this page.

Who wrote this paper?

Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, Daniel J. Baillache, Stephen Croke, Asier Unciti‐Broceta.

What is the DOI of this paper?

10.1021/acs.jmedchem.1c00963, permanently at https://doi.org/10.1021/acs.jmedchem.1c00963. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.